CHICAGO - Roche's current focus in oncology is on establishing longer treatment durations for its oncologics, including its mega-blockbuster Avastin (bevacizumab). "This year, the key message for us is treatment duration," Pharmaceuticals Chief Operating Officer Pascal Soriot said in opening a June 6 analyst event held in conjunction with the American Society of Clinical Oncology annual meeting in Chicago.Roche's highlights of research presented at ASCO emphasize longer periods of utilization of...